Jacobs Levy Equity Management, Inc Atea Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 509,471 shares of AVIR stock, worth $1.63 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
509,471
Previous 564,898
9.81%
Holding current value
$1.63 Million
Previous $1.87 Million
8.72%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
52.4MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$29.1 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$21.2 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$17.4 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.85MShares$15.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$14.7 Million1.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $266M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...